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Background: This Phase III, randomised, double-blind, multicentre trial (FALCON; NCT01602380) 
compared the selective estrogen receptor (ER) degrader (SERD) fulvestrant with anastrozole in patients 
with ER- and/or progesterone receptor-positive locally advanced or metastatic breast cancer who had 
not received prior hormonal therapy. 
Methods: Patients were randomised 1:1 to fulvestrant (500 mg IM on Days 0, 14, 28, then each 28 days) 
or anastrozole (1 mg daily). The primary endpoint was progression-free survival (PFS), assessed via 
RECIST 1.1, surgery/radiotherapy for disease worsening, or death. Secondary endpoints were: overall 
survival (OS); objective response rate (ORR, complete response [CR] or partial response [PR]); duration 
of response (DoR); expected DoR (EDoR); clinical benefit rate (CBR; CR, PR, or stable disease ≥24 weeks); 
duration of clinical... 
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